

## Pharma & Healthcare Update

April 01, 2021

### COMMERCIALISATION OF HEALTHCARE IN INDIA: OVERVIEW

India is home to some of the world's largest pharmaceutical companies and makes a significant contribution to the global output of drugs each year. India's reputation as the pharmacy of the world has only grown in recent years. In the medical device sector as well, India is on its way to making a mark globally. The growth of the Indian pharmaceutical and medical device industry can be attributed in part to the well-established regulatory framework governing drugs and medical devices manufactured and marketed in India. Medicinal products have been regulated in India since the 1940s and the government has been making efforts in recent years to ensure the manner of regulating drugs and medical devices is in line with global standards. This has encouraged many foreign players to consider marketing their products in India as well as sourcing their products from India to meet the demand in other jurisdictions.

In this guide, Dr. Milind Antani, Darren Punnen and Shreya Shenolikar provide a comprehensive overview of the regulatory framework applicable to drugs and medical devices. The guide covers the entire supply chain from approval of drugs and medical devices to their sale to the end consumer. They have also provided information on the manner in which pharmaceutical adjacent products such as alternative medicinal products and nutraceuticals are regulated.

The complete article can be accessed [here](#).

Reproduced from Practical Law with the permission of the publishers. For further information, visit [practicallaw.com](https://practicallaw.com)

– Shreya Shenolikar, Darren Punnen & Dr. Milind Antani  
You can direct your queries or comments to the authors

### DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

### Research Papers

#### Littler International Guide (India) 2024

November 08, 2024

#### Unmasking Deepfakes

October 25, 2024

#### Are we ready for Designer Babies

October 24, 2024

### Research Articles

#### The Bitcoin Effect

November 14, 2024

#### Acquirers Beware: Indian Merger Control Regime Revamped!

September 15, 2024

#### Navigating the Boom: Rise of M&A in Healthcare

August 23, 2024

### Audio

#### Digital Lending - Part 1 - What's New with NBFC P2Ps

November 19, 2024

#### Renewable Roadmap: Budget 2024 and Beyond - Part I

August 26, 2024

#### Renewable Roadmap: Budget 2024 and Beyond - Part II

August 26, 2024

### NDA Connect

Connect with us at events, conferences and seminars.

### NDA Hotline

[Click here to view Hotline archives.](#)

### Video

#### "Investment return is not enough" Nishith Desai with Nikunj Dalmia (ET Now) at FI8 event in Riyadh

October 31, 2024

#### Analysing SEBI's Consultation Paper on Simplification of registration for FPIs

September 26, 2024

